(Reuters) -British drugmaker GSK said on Wednesday administration of its respiratory syncytial virus (RSV) vaccine and shingles shot together generated the same immune response in a late-stage trial ...
LONDON (Reuters) - An experimental shingles vaccine from GlaxoSmithKline has produced impressive results in a late-stage study, giving the group's expanding vaccine unit a potential $1 billion boost.
Brooke Shields convenes other celebrities, influencers and patient advocates over 50 to discuss the power of aging and how to protect their health Shields directs a short film, encouraging adults 50 ...
GSK touts co-administration data for RSV, shingles vaccines as narrowed CDC guidance threatens sales
This summer, GSK cut its yearly vaccine sales projection on the back of a narrowed recommendation for adult respiratory syncytial virus (RSV) vaccines from the Centers for Disease Control and ...
(RTTNews) - GSK plc (GSK, GSK.L) announced positive topline data from the phase 3 trial in adults 50 years and older evaluating the immunogenicity, reactogenicity and safety of AREXVY when ...
GSK (NYSE:GSK) announced Tuesday that its shingles vaccine, Shingrix, reduced the risk of dementia with a statistically significant effect compared to Merck's (MRK) pneumonia vaccine, Pneumovax 23, ...
LONDON (Reuters) - GlaxoSmithKline has filed its shingles vaccine Shingrix for U.S. regulatory approval, the drugmaker said on Monday, bringing the potential $1 billion-a-year seller a step closer to ...
GSK takes advantage of natural experiment to study whether shingles vaccine can reduce dementia risk
After multiple studies have suggested a link between its shingles vaccine and dementia prevention, GSK is taking advantage of a natural experiment to look for more definitive evidence that the shot ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback